Delving into the Latest Updates on Yagin (Savient Pharmaceuticals, Inc.) with Synapse

Overview

Basic Info

Drug Type

Recombinant protein

Synonyms

yagin, yagin (Savient Pharmaceuticals, Inc.)

Target

factor Xa

Mechanism

factor Xa inhibitors(Factor Xa inhibitors)

Therapeutic Areas

Cardiovascular Diseases

Active Indication-

Inactive Indication

Thromboembolism

Originator Organization

Savient Pharmaceuticals, Inc.

Active Organization-

Inactive Organization

Savient Pharmaceuticals, Inc.

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

OBJECTIVETo compare the efficacy of Yagin, a factor Xa inhibitor derived from the leech Hirudo medicinalis, with those of heparin and hirudin as adjuncts to recombinant tissue-type plasminogen activator (rTPA) thrombolysis in a rabbit thrombosis model.METHODSThirty-one animals were allocated randomly to three groups, all administered four boluses of 0.25 mg/kg rTPA every 10 min for 30 min, 17 mg/kg aspirin intravenously, and heparin (as a 100 IU/kg bolus followed by infusion of 50 IU/kg heparin per h), hirudin (as a 2 mg/kg bolus followed by infusion of 1 mg/kg hirudin per h), or Yagin (as an 80 micrograms/kg bolus followed by infusion of 43 micrograms/kg Yagin per h).RESULTSAdministration of Yagin was associated with a significant acceleration of the reflow time, this time being 14.5 +/- 1.2 min with Yagin, 25.8 +/- 5.2 min with heparin (P < 0.0001, versus Yagin), and 28.7 +/- 16.0 min with hirudin (P = 0.012, versus Yagin). Overall patency did not differ significantly among the three groups.CONCLUSIONSAt the indicated single doses, inhibition of factor Xa by a relatively low concentration of Yagin was found to be superior than that with either heparin or hirudin for accelerating rTPA thrombolysis.

100 Deals associated with Yagin (Savient Pharmaceuticals, Inc.)

Login to view more data